Vanguard Group Inc. Has $143.49 Million Stock Holdings in LivaNova PLC $LIVN

Vanguard Group Inc. lifted its holdings in LivaNova PLC (NASDAQ:LIVN) by 1.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,332,051 shares of the company’s stock after acquiring an additional 34,812 shares during the quarter. Vanguard Group Inc. owned approximately 4.27% of LivaNova worth $143,491,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. State of Wyoming acquired a new position in shares of LivaNova during the second quarter valued at $31,000. EverSource Wealth Advisors LLC increased its position in LivaNova by 998.4% in the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the period. Quarry LP bought a new stake in LivaNova during the 3rd quarter worth about $36,000. UMB Bank n.a. raised its holdings in LivaNova by 63.0% during the 3rd quarter. UMB Bank n.a. now owns 792 shares of the company’s stock worth $41,000 after purchasing an additional 306 shares during the last quarter. Finally, Bayforest Capital Ltd lifted its position in LivaNova by 44.8% during the 3rd quarter. Bayforest Capital Ltd now owns 918 shares of the company’s stock valued at $48,000 after purchasing an additional 284 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

LivaNova Trading Down 2.5%

NASDAQ:LIVN opened at $70.09 on Tuesday. LivaNova PLC has a twelve month low of $41.01 and a twelve month high of $72.78. The company has a quick ratio of 1.11, a current ratio of 1.33 and a debt-to-equity ratio of 0.24. The business has a 50 day moving average price of $64.02 and a two-hundred day moving average price of $62.38. The company has a market cap of $3.85 billion, a P/E ratio of 35.94 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.13. The company had revenue of $362.26 million for the quarter, compared to the consensus estimate of $346.05 million. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm’s revenue was up 14.3% compared to the same quarter last year. During the same period last year, the company earned $0.88 earnings per share. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. As a group, analysts expect that LivaNova PLC will post 3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on LIVN shares. Stifel Nicolaus set a $80.00 price target on shares of LivaNova in a research report on Wednesday, February 25th. Mizuho raised their price objective on LivaNova from $85.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Robert W. Baird decreased their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Piper Sandler restated an “overweight” rating and issued a $85.00 price target on shares of LivaNova in a report on Thursday, February 19th. Finally, Weiss Ratings raised LivaNova from a “sell (d+)” rating to a “hold (c)” rating in a research report on Thursday. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, LivaNova currently has an average rating of “Moderate Buy” and a consensus target price of $77.22.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.